One of today's biggest movers in the biotech sector is RedHill Biopharma (NASDAQ:RDHL), a little-known specialty player in the space focusing on gastrointestinal and infectious diseases. Today, RDHL stock is up more than 75% in early afternoon trading on an announcement from the company that it has seen positive results for a key Phase 3 study. This study focused on patients suffering from Chron's disease, assessing how its RHB-104 treatment would compare to the current standards of care in the industry. Im ...